Dapagliflozin Viatris

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

dapagliflozin

Available from:

Viatris Limited

ATC code:

A10BK01

INN (International Name):

dapagliflozin

Therapeutic group:

Lijekovi koji se koriste u dijabetesu

Therapeutic area:

Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic

Therapeutic indications:

Type 2 diabetes mellitusDapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. Heart failureDapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Chronic kidney diseaseDapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease.

Authorization status:

odobren

Authorization date:

2023-03-24

Patient Information leaflet

                                58
B. UPUTA O LIJEKU
59
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
DAPAGLIFLOZIN VIATRIS 5 MG FILMOM OBLOŽENE TABLETE
DAPAGLIFLOZIN VIATRIS 10 MG FILMOM OBLOŽENE TABLETE
dapagliflozin
PAŽLJIVO PRO
č
ITAJTE CIJELU UPUTU PRIJE NEGO PO
č
NETE UZIMATI OVAJ LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sa
č
uvajte ovu uputu. Možda
ć
ete je trebati ponovno pro
č
itati.
-
Ako imate dodatnih pitanja, obratite se svom lije
č
niku, ljekarniku ili medicinskoj sestri.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi,
č
ak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti lije
č
nika ili ljekarnika. To
uklju
č
uje i svaku mogu
ć
u nuspojavu koja nije navedena u ovoj uputi. Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Dapagliflozin Viatris i za što se koristi
2.
Što morate znati prije nego po
č
nete uzimati Dapagliflozin Viatris
3.
Kako uzimati lijek Dapagliflozin Viatris
4.
Mogu
ć
e nuspojave
5.
Kako
č
uvati lijek Dapagliflozin Viatris
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE DAPAGLIFLOZIN VIATRIS I ZA ŠTO SE KORISTI
ŠTO JE DAPAGLIFLOZIN VIATRIS
Dapagliflozin Viatris sadrži djelatnu tvar dapagliflozin. Pripada
skupini lijekova koji se zovu
„inhibitori suprijenosnika natrija i glukoze 2 (SGLT2)“, a djeluju
tako da blokiraju protein SGLT2 u
bubrezima. Blokiranje tog proteina dovodi do uklanjanja še
ć
era (glukoze) u krvi, soli (natrija) i vode
iz tijela kroz mokra
ć
u.
ŠTO JE DAPAGLIFLOZIN VIATRIS I ZA ŠTO SE KORISTI
Dapagliflozin Viatris se primjenjuje za lije
č
enje:
•
ŠE
ć
ERNE BOLESTI TIPA 2
•
u odraslih i djece u dobi od 10 i više godina
•
ako se še
ć
erna bolest tipa 2 ne može kontrolirati dijetom i tjelovježbom.
•
Dapagliflozin Viatris se može uzimati samostalno ili zajedno s drugim
lijekovima za
lije
č
enje še
ć
erne bolesti.
•
Važno je da nastavite slijediti savjete o dijeti i tjelovježbi koje
Vam je dao Vaš lije
č
nik,
ljekarnik ili medicinska sest
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Dapagliflozin Viatris 5 mg filmom obložene tablete
Dapagliflozin Viatris 10 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Dapagliflozin Viatris 5 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 5 mg dapagliflozina.
_ _
_Pomo_
ć
_na tvar s poznatim u_
č
_inkom _
Jedna tableta od 5 mg sadrži 24 mg laktoze.
Dapagliflozin Viatris 10 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 10 mg dapagliflozina.
_ _
_Pomo_
ć
_na tvar s poznatim u_
č
_inkom _
Jedna tableta od 10 mg sadrži 48 mg laktoze.
Za cjeloviti popis pomo
ć
nih tvari, vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta)
Dapagliflozin Viatris 5 mg filmom obložena tableta
Žuta, okrugla, bikonveksna filmom obložena tableta promjera
približno 7,2 mm s utisnutom oznakom
„5“ na jednoj strani i bez oznake na drugoj strani.
Dapagliflozin Viatris 10 mg filmom obložena tableta
Žuta, bikonveksna tableta u obliku romba dimenzija približno 11 x 8
mm, s utisnutom oznakom „10“
na jednoj strani i bez oznake na drugoj strani.
4.
KLINI
Č
KI PODACI
4.1
TERAPIJSKE INDIKACIJE
Še
ć
erna bolest tipa 2
Dapagliflozin Viatris je indiciran za lije
č
enje odraslih osoba i djece u dobi od 10 i više godina s
nedovoljno dobro reguliranom še
ć
ernom boleš
ć
u tipa 2, kao dodatak dijeti i tjelovježbi
-
kao monoterapija kada se primjena metformina ne smatra prikladnom zbog
nepodnošenja
-
kao dodatak drugim lijekovima za lije
č
enje še
ć
erne bolesti tipa 2
Za rezultate ispitivanja koji se odnose na primjenu u kombinaciji s
drugim lijekovima, u
č
inke na
regulaciju glikemije, kardiovaskularne i bubrežne doga
đ
aje te ispitivane populacije vidjeti
dijelove 4.4, 4.5 i 5.1.
3
Zatajenje srca
Dapagliflozin Viatris je indiciran u odraslih bolesnika za lije
č
enje simptomatskog kroni
č
nog zatajenja
srca s reduciranom ejekcijskom frakcijom.
Kroni
č
na bubrežna bolest
Dapagliflozin Viatris je indiciran u odraslih bol
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 18-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 18-01-2024
Public Assessment Report Public Assessment Report Bulgarian 04-04-2023
Patient Information leaflet Patient Information leaflet Spanish 18-01-2024
Public Assessment Report Public Assessment Report Spanish 04-04-2023
Patient Information leaflet Patient Information leaflet Czech 18-01-2024
Public Assessment Report Public Assessment Report Czech 04-04-2023
Patient Information leaflet Patient Information leaflet Danish 18-01-2024
Public Assessment Report Public Assessment Report Danish 04-04-2023
Patient Information leaflet Patient Information leaflet German 18-01-2024
Public Assessment Report Public Assessment Report German 04-04-2023
Patient Information leaflet Patient Information leaflet Estonian 18-01-2024
Public Assessment Report Public Assessment Report Estonian 04-04-2023
Patient Information leaflet Patient Information leaflet Greek 18-01-2024
Public Assessment Report Public Assessment Report Greek 04-04-2023
Patient Information leaflet Patient Information leaflet English 18-01-2024
Public Assessment Report Public Assessment Report English 04-04-2023
Patient Information leaflet Patient Information leaflet French 18-01-2024
Public Assessment Report Public Assessment Report French 04-04-2023
Patient Information leaflet Patient Information leaflet Italian 18-01-2024
Public Assessment Report Public Assessment Report Italian 04-04-2023
Patient Information leaflet Patient Information leaflet Latvian 18-01-2024
Public Assessment Report Public Assessment Report Latvian 04-04-2023
Patient Information leaflet Patient Information leaflet Lithuanian 18-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-01-2024
Public Assessment Report Public Assessment Report Lithuanian 04-04-2023
Patient Information leaflet Patient Information leaflet Hungarian 18-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 18-01-2024
Public Assessment Report Public Assessment Report Hungarian 04-04-2023
Patient Information leaflet Patient Information leaflet Maltese 18-01-2024
Public Assessment Report Public Assessment Report Maltese 04-04-2023
Patient Information leaflet Patient Information leaflet Dutch 18-01-2024
Public Assessment Report Public Assessment Report Dutch 04-04-2023
Patient Information leaflet Patient Information leaflet Polish 18-01-2024
Public Assessment Report Public Assessment Report Polish 04-04-2023
Patient Information leaflet Patient Information leaflet Portuguese 18-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 18-01-2024
Public Assessment Report Public Assessment Report Portuguese 04-04-2023
Patient Information leaflet Patient Information leaflet Romanian 18-01-2024
Public Assessment Report Public Assessment Report Romanian 04-04-2023
Patient Information leaflet Patient Information leaflet Slovak 18-01-2024
Public Assessment Report Public Assessment Report Slovak 04-04-2023
Patient Information leaflet Patient Information leaflet Slovenian 18-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 18-01-2024
Public Assessment Report Public Assessment Report Slovenian 04-04-2023
Patient Information leaflet Patient Information leaflet Finnish 18-01-2024
Public Assessment Report Public Assessment Report Finnish 04-04-2023
Patient Information leaflet Patient Information leaflet Swedish 18-01-2024
Public Assessment Report Public Assessment Report Swedish 04-04-2023
Patient Information leaflet Patient Information leaflet Norwegian 18-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 18-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 18-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 18-01-2024

Search alerts related to this product